Phenylketonuria (PKU) has been detected on the newborn screening programme since the 1960s. Although it is recognised that dietary treatment is successful in avoiding the severe mental retardation associated with untreated PKU, the long-term outcome for adults remains unclear. The Medical Research Council recommends that the diet be followed for life. This paper discusses the relevance of the findings of neurological deterioration, neuropsychological problems and brain imaging in adults with PKU. It suggests an approach to follow-up for adults with PKU including neurological assessments, awareness of nutritional deficiencies, educational requirements and the risks of maternal PKU.
References
1.
Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register. Br Med J Clin Res Ed1981;282: 1680–4.
2.
KnoxWE, Phenylketonuria. In: StanburyJBWyngaardenJBFredericksonDS, editors. The Metabolic Basis of Inherited Disease, 3rd edn.New York: McGraw-Hill, 1972: 266–95.
3.
BickelHGerrardJHickmansE.Influence of phenylalanine intake on phenylketonuria. Lancet1953;ii: 812.
4.
BickelHGerrardJHickmansEM. The influence of phenylalanine intake on the chemistry and behavior of a phenylketonuric child. Acta Paediatr1954;43: 64.
5.
WoolfLIGriffithsRMoncrieffA.Treatment of phenylketonuria with a diet low in phenylalanine. BMJ1955;1: 57.
6.
GuthrieRSusiA.A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics1963;32: 338–43.
7.
ClarkBJ. After a positive Guthrie - what next? Dietary management for the child with phenylketonuria. Eur J Clin Nutr1992;46 (Suppl 1): S33–S39.
8.
ScriverCRKaufmanSEisensmithRWooSLC. The hyperphenylalaninemias. In: ScriverCRBeaudetALSlyWSValleD, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 1995: 1015–76.
9.
BickUFahrendorfGLudolphACVassalloPWeglageJUllrichK.Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur J Pediatr1991;150: 185–9.
ThompsonAJSmithIBrentonDYoulBDRylanceGDavidsonDCNeurological deterioration in young adults with phenylketonuria. Lancet1990;336: 602–5.
12.
Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria. BMJ1993;306: 115–9.
13.
Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch Dis Child1993;68: 426–7.
14.
FitzgeraldBMorganJKeeneNRollinsonRHodgsonADalrymple-SmithJ.An investigation into diet treatment for adults with previously untreated phenylketonuria and severe intellectual disability. J Intellect Disabil Res2000;44 (Pt 1): 53–9.
15.
SmithI.The hyperphenylalaninaemias. In: LloydJKScriverCR, editors. Genetic and Metabolic Disease in Pediatrics. London: Butterworths, 1985: 166–210.
16.
GuttlerF.Modern techniques of differentiating the various phenotypes of phenylketonuria. Postgrad Med J1989;65 (Suppl 2): S2–6.
17.
DiLellaAGKwokSCLedleyFDMarvitJWooSL. Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene. Biochemistry1986;25: 743–9.
18.
TyfieldLAStephensonACockburnFHarvieABidwellJLWoodNASequence variation at the phenylalanine hydroxylase gene in the British Isles. Am J Hum Genet1997;60: 388–96.
19.
MalamudN.Neuropathology of phenylketonuria. J Neuropathol1966;25: 254–68.
20.
PoserCMvan BogaertL.Neuropathologic observations in phenylketonuria. Brain1959;82: 1–9.
21.
HommesFA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. Biochem Med Metab Biol1991;46: 277–87.
22.
DyerCAKendlerAPhilibotteTGardinerPCruzJLevyHL. Evidence for central nervous system glial cell plasticity in phenylketonuria. J Neuropathol Exp Neurol1996;55: 795–814.
23.
WalterJH. Late effects of phenylketonuria. Arch Dis Child1995;73: 485–6.
24.
SmithIBeasleyM.Intelligence and behaviour in children with early treated phenylketonuria. A report from the MRC/DHSS Phenylketonuria Register. Eur J Clin Nutr1989;43 (Suppl 1): 1–5.
25.
SmithIBeasleyMGAdesAE. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child1991;66: 311–6.
26.
SmithIBeasleyMGWolffOHAdesAE. Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. J Pediatr1988;112: 403–8.
27.
KrauseWHalminskiMMcDonaldLDemburePSalvoRFreidesDBiochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. J Clin Invest1985;75: 40–8.
28.
PietzJSchmidtEMatthisPKobialkaBKutschaAde SonnevilleL.EEGs in phenylketonuria. I: Follow-up to adulthood; II: Short-term diet-related changes in EEGs and cognitive function. Dev Med Child Neurol199335: 54–64.
SeashoreMRFriedmanENovellyRABapatV.Loss of intellectual function in children with Phenylketonuria after relaxation of dietary Phenylalanine restriction. Pediatrics1985;75: 226–32.
31.
WelshMCPenningtonBFOzonoffS.Rouse B. McCabe ER. Neuropsychology of early-treated Phenylketonuria: specific executive function deficits. Child Dev1990;61: 1697–713.
32.
BrunnerRLBerchDBBerryH.Phenylketonuria and complex spatial visualization: an analysis of information processing. Dev Med Child Neurol1987;29: 460–8.
33.
DiamondACiaramitaroVDonnerEDjaliSRobinsonMB. An animal model of early-treated PKU. J Neurosci1994;14: 3072–82.
34.
BattistiniSde StefanoNParlantiSFedericoA.Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. Funct Neurol1991;6: 177–80.
35.
ThompsonAJTillotsonSSmithIKendallBMooreSGBrentonDP. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain1993;116: 811–21.
36.
ClearyMAWalterJHWraithJEJenkinsJPAlaniSMTylerKMagnetic resonance imaging of the brain in phenylketonuria. Lancet1994;344: 87–90.
37.
BickUUllrichKStoberUMollerHSchuiererGLudolphACWhite matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur J Pediatr1993;152: 1012–20.
38.
PenningtonBFvan DoorninckWJMcCabeLLMcCabeER. Neuropsychological deficits in early treated phenylketonuric children. Am J Ment Defic1985;89: 467–74.
39.
DiamondAPrevorMBCallenderGDruinDP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev1997;62: i–208.
40.
ArnoldGLKramerBMKirbyRSPlumeauPBBlakelyEMSangerCLFactors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. Acta Paediatr1998;87: 565–70.
41.
SchmidtEBurgardPRuppA.Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. Eur J Pediatr1996;155 (Suppl 1): S82–S86.
42.
LouHCToftPBAndresenJMikkelsenIOlsenBGuttlerFAn occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia. J Inherit Metab Dis1992;15: 687–95.
43.
ClarkeJTGatesRDHoganSEBarrettMMacDonaldGW. Neuropsychological studies on adolescents with phenylketonuria returned to phenylalanine-restricted diets. Am J Ment Retard1987;92: 255–62.
44.
PearsenKDGean MartonADLevyHLDavisKR. Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology1990;177: 437–40.
45.
ClearyMAWalterJHWraithJEWhiteFTylerKJenkinsJP. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J Pediatr1995;127: 251–5.
46.
PietzJKreisRSchmidtHMeyding LamadeUKRuppABoeschC.Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology1996;201: 413–20.
47.
MoatsRAKochRMoseleyKGuldbergPGuttlerFBolesRGBrain phenylalanine concentration in the management of adults with phenylketonuria. J Inherit Metab Dis2000;23: 7–14.
48.
MollerHEVermathenPUllrichKWeglageJKochHGPetersPE. In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Neuropediatrics1995;26: 199–202.
49.
MollerHEWeglageJWiedermannDVermathenPBickUUllrichK.Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Brain Res1997;778: 329–37.
50.
MollerHEWeglageJWiedermannDUllrichK.Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab1998;18: 1184–91.
51.
WeglageJMollerHEWiedermannDCipcic-SchmidtSZschockeJUllrichK.In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations. J Inherit Metab Dis1998;21: 81–2.
52.
BurgardPBremerHJBuhrdelPClemensPCMonchEPrzyrembelHRationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr1999;158: 46–54.
53.
NSPKU. Management of PKU. A consensus document for the diagnosis and management of children, adolescents and adults with phenylketonuria. Tyne & Wear: NSPKU, 1999.
54.
RobinsonMWhiteFJClearyMAWraithELamWKWalterJH. Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J Pediatr2000;136: 545–7.
55.
AungTTKliedAMcGinnJMcGinnT.Vitamin B12 deficiency in an adult phenylketonuric patient. J Inherit Metab Dis1997;20: 603–4.
56.
HanleyWBFeigenbaumASClarkeJTSchoonheytWEAustinVJ. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. Eur J Pediatr1996;155 (Suppl 1): S145–7.
57.
LeePSmithIPiesowiczABrentonD.Spastic paraparesis after anaesthesia. Lancet1999;353: 554.
58.
LevyHLWaisbrenSE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. N Engl J Med1983;309: 1269–74.
59.
KochRLevyHLMatalonRRouseBHanleyWAzenC.The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. Am J Dis Child1993;147: 1224–30.
60.
KochRLevyHHanleyWMatalonRRouseBTrefzFOutcome implications of the International Maternal Phenylketonuria Collaborative Study (MPKUCS): 1994. Eur J Pediatr1996;155 (Suppl 1): S162–S164.
61.
AusticRESuCLStruppBJLevitskyDA. Effects of dietary mixtures of amino acids on fetal growth and maternal and fetal amino acid pools in experimental maternal phenylketonuria. Am J Clin Nutr1999;69: 687–96.
62.
PietzJKreisRRuppAMayatepekERatingDBoeschCLarge neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest1999;103: 1169–78.
63.
SarkissianCNShaoZBlainFPeeversRSuHHeftRA different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA1999;96: 2339–44.
64.
FangBEisensmithRCLiXHFinegoldMJShedlovskyADoveWGene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirusmediated hepatic gene transfer. Gene Ther1994;1: 247–54.
